Kornimate/medical-research-clean huggingface dataset:
bilateral internal iliac artery ligation before cesarean hysterectomy

Conditions: Placenta Accreta

Summary: all women with placenta accreta will be managed by upper segment cesarean section followed by cesarean hysterectomy without attempts of placental removal. women were randomized to either bilateral internal iliac artery ligation before hysterectomy and after fetal extraction or no additional intervention

all women with placenta accreta will be managed by upper segment cesarean section followed by cesarean hysterectomy without attempts of placental removal. women were randomized to either bilateral internal iliac artery ligation before hysterectomy and after fetal extraction or no additional intervention. midline incision in the all patients is preferred. the retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. the ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. the fat and loose connective tissue around the iia and vein were removed and a right-angle clamp was passed beneath the iia from the lateral to the medial side approximately 4 cm distal to its origin. using an absorbable suture, the iia was ligated doubly in all cases . pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. the procedure was then repeated on the other side.

Eligibility criteria:
inclusion criteria: * women with suspected placenta accreta * scarred uterus * approving hysterectomy exclusion criteria: * women needed conservative surgery * women with coagulopathy or bleeding disorders
preference for a prefilled syringe or smartject™ device for delivering golimumab in participants suffering from moderate-to-severe ulcerative colitis (mk-8259-027)

Conditions: Ulcerative Colitis

Summary: this study is designed to determine whether ulcerative colitis participants prefer delivery of golimumab via a prefilled syringe or the smartject™ device.


Eligibility criteria:
inclusion criteria: * anti-tumor necrosis factor (anti-tnf) naive participants with a diagnosis of moderate-to-severe ulcerative colitis. * mayo clinic score \>= 6, including endoscopic subscore \>=2; * previous conventional therapy for a period of at least 3 months with aminosalicylates and at least 3 months with corticosteroids or 6-mercaptopurine (6-mp) or azathioprine (aza), unless the participant is intolerant to, or has contraindications to these treatments; * anti-tnf experienced participants with an established diagnosis of moderate-to-severe ulcerative colitis, either not responding or partially responding to treatment with remicade (infliximab). the participant must also meet the following criteria prior to initiating first-line anti-tnf treatment: mayo score ≥ 6, including an endoscopic subscore ≥ 2; and previous conventional therapy of at least 3 months with aminosalicylates and at least 3 months with corticosteroids or 6-mercaptopurine (6-mp) or azathioprine (aza), unless the participant is intolerant to or have medical contraindications for such therapies (should be documented); * sexually active women of child-bearing potential must agree to use a medically accepted method of contraception while receiving study drug and for 6 months after the stop of study drug exclusion criteria: * has a history of prior self-injection for any reason; * has concomitant use of other biologic agents; * has active tuberculosis (tb) within 12 months prior to the first injection or has suspected latent tb as indicated by a positive tuberculin skin test. * has an active clinical non-tuberculous mycobacterial infection or opportunistic infection within 6 months prior to the first injection; * has had an active infection and/or serious infection within 6 months prior to the first study drug administration; * has had a live viral or bacterial vaccination within 3 months prior to the first study injection or bacillus calmette-guerin vaccination within 12 months prior to the first study drug injection; * has evidence of heart failure of new york heart association class 3-4; * has a history of demyelinating disease such as multiple sclerosis or optic neuritis; * has a history of systemic lupus erythematosus; * has a history of lymphoproliferative disease, or any unknown malignancy or history of malignancy within the prior 5 years, with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence; * has had an active hepatitis b infection; * has an allergy or sensitivity to golimumab or its excipients; * is pregnant or breast feeding; * is sensitive to latex.
a syndemic based intervention for msm with high risk behavior: design of a randomized controlled trial

Conditions: Risk Behavior

Summary: the purpose of this randomized controlled intervention study at the sti outpatient clinic of amsterdam is to answer the following questions : does a personalised behaviour intervention comprising of targeted in-depth screening on mental health problems and drug use and, in case identified, subsequent linkage to care increase help seeking behaviour, and decrease risk behaviour in msm who are at high risk for stis and hiv?


Eligibility criteria:
inclusion criteria: * msm * sufficient understanding of dutch or english and * 2 stis in the last 24 months or a pep treatment for hiv negative msm exclusion criteria: * men will be excluded if they are not able to complete follow-up or otherwise deemed by clinic staff to be unsuited for participation.

Keywords: hiv drug abuse msm risk behavior sexually transmitted diseases sexually transmitted infections
hiv prevention and care of psychological trauma in vulnerable rwandan youth

Conditions: Acquired Immunodeficiency Syndrome; Stress Disorders, Post-Traumatic

Summary: the investigators propose a prospective single arm pilot cohort study of 100 youth (ages 15-25) to evaluate the feasibility of this project. a convenience sample of subjects will be enrolled on a voluntary basis from those who come to the day care center located in nyanza, a district of the southern province, in rwanda.

the investigators propose a prospective single arm pilot cohort study of 100 youth (ages 15-25) to evaluate the feasibility of this project. a convenience sample of subjects will be enrolled on a voluntary basis from those who come to the day care center located in nyanza, a district of the southern province, in rwanda. uyisenga n'manzi identified 400 youths in nyanza region, organized in 4 groups, each of them between 160 to 100 youths. many of those orphans go to school in any school in the country. this situation will be taken into account for the calendar of activities and for organization of the regular interviews and evaluations. random selection of the participant will be ensured by choosing study subjects from a list and attributing them an arbitrary number. the random selection will be weighted by the size of the household group across the 4 groups in the nyanza region. selection will also be in proportion of sex and age groups. in this manner 100 youth will be picked with 20 "backup" to account for refusals and drop-outs. those selected youth will be asked to participate to the pilot study and will fill the consent form under the guidance of an external observer (not one of the service providers of the project to avoid consent obtained by social pressure). once enrolled, the subjects will be followed during 1 year with serial evaluations at baseline, 3, 6, 9 and 12 months.

Eligibility criteria:
inclusion criteria: * 100 orphans/vulnerable youth aged 15 to 25 will be recruited through their participation at the day care center, on a voluntary basis. exclusion criteria: * age less than 15 or greater than 25 and not participating in the day care center
ultrasonography-guided real-time modular systems for hand therapy

Conditions: Health Adults; Patients With Traumatic Hand Injury

Summary: this study aimed to develop an ultrasonography-guided real-time modular system and try to apply it to clinical hand therapy using. this study was divided into two parts. the first part is an observational study design. the ultrasonography-guided real-time modular system will be developed and integrated, and its overall reliability and validity will be tested in this part. once the software and hardware of the modular system has been established, numerous hand-related ultrasonography data will be collected for building an artificial intelligence model for detecting the anatomic structures in hand, evaluating the status of the tissues in hand. the second part is an interventional study design. the clinical application of the modular system on hand injured patients is conducted, and the biofeedback mechanics will also be defined in the second part. the patients will be recruited into the research to receive both traditional rehabilitation and the one which combines with biofeedback training via the modular system. the effect of the traditional and biofeedback-added rehabilitation will be compared.


Eligibility criteria:
【patients】 inclusion criteria: * traumatic hand injury (distal from wrist joint above 8 weeks and within one year) * able to do active motion and resistive activities * understand and cooperate the experiment exclusion criteria: * burn, amputees or has history of arthritis * combined with other central or peripheral nerve deficits which cause difficulty in movements 【healthy subjects】 inclusion criteria: * no history of traumatic hand injury and other hand related conditions * understand and cooperate the experiment exclusion criteria: * burn, amputees or has history of arthritis * combined with other central or peripheral nerve deficits which cause difficulty in movements

Keywords: ultrasonography-guided biofeedback hand therapy
tacrolimus for thrombocytopenia in ss

Conditions: Sjogren Syndrome With Other Organ Involvement

Summary: this 12-week randomized, open-label study evaluates the efficacy and safety of tacrolimus for sjogren's syndrome patients with thrombocytopenia.

this study evaluates the efficacy and safety of tacrolimus for the treatment of thrombocytopenia in sjogren's syndrome patients.

Eligibility criteria:
inclusion criteria: * diagnosis of sjogren's syndrome according to the 2002 revised american-european consensus group (aecg) criteria. * baseline platelet counts within 30-80×109/l. exclusion criteria: * concomitant other systemic autoimmune diseases. * severe complications of sjogren's syndrome. * abnormal laboratory tests such as: white blood cell count \ 1.5 uln, serum creatine \> 1.5 mg/dl. * received glucocorticoids, immunosuppressants, or biological agents within 3 months. * active acute or chronic infections. * history of malignancy. * pregnancy or breastfeeding.

Keywords: sjogren's syndrome thrombocytopenia tacrolimus
familiar fatal insomnia: preventive treatment with doxycycline in subject with disease risk

Conditions: Familial Fatal Insomnia

Summary: the neurodegenerative disorders is a class o pathologies including very common diseases as alzheimer or parkinson or very rare as fatal familial insomnia (ffi), the progression of the disease with no therapeutic remedy is the common tract of these disorders. the aim of this project is to carry out a preventive treatment in subjects with genetic risk to develop ffi to avoid the establishment of the disease. ffi is a rare genetic neurodegenerative disease characterized by disrupted sleep, autonomic hyperactivation and motor abnormalities with fatal exitus. ffi is inherited in an autosomal dominant fashion and is linked to the d178n mutation in the prion protein gene (prnp) in association with a methionine at the polymorphic codon 129 (d178n/m129). about thirty ffi pedigrees have been described worldwide, the mfirst case being reported in 1986 in northern italy. this patient turned out to belong to large kindred, which spans 7 generations dating back to the eighteenth century. many people belonging to this geneaology still live in the veneto region of italy, and they are part of an association. the genetic screening of 85 subjects belonging to this family permitted to identify the mutation carriers. since the disease is aggressive and the affected people usually died within thirteen months from the onset, the possibility of an efficacious therapy when the disease become evident is unrealistic. this condition indicates in a preventive approach the better condition to affect the disease. experimental studies and clinical observation indicated the antibiotic doxycycline (doxy) as a potential candidate for a treatment in ffi subjects. the age with maximal risk to get the disease is between 50 and 55 years old. thus the carriers that were born between 1958 and 1969 will be recruited for a preventive treatment with doxy for ten years, at the end of this period or before we can establish if doxy can be useful to avoid the development of ffi.


Eligibility criteria:
inclusion criteria: * subjects aged 44 to 53 years; * no conditions known to be contraindications to the use of tetracyclines; * written informed consent. exclusion criteria: * end stage liver, * heart and renal disease, * active malignancy, * female subjects who are pregnant or lactating
clopidogrel monotherapy in patients with high bleeding risk

Conditions: Bleeding Complications

Summary: the goal of this research is to show that a shorter duration of two antiplatelet medications (compared to the standard of care) is safe and effective while reducing the risk of bleeding complications. bleeding complications can cause significant problems (hospitalizations, need for blood transfusions, and even death) for patients on antiplatelet medications after coronary stents. researchers hope to show that reducing the time on two antiplatelet agents in patients at high risk for these bleeding complications will reduce the number of bleeding events while not causing any increase in cardiovascular complications (heart attack, stent malfunction, death).


Eligibility criteria:
inclusion criteria: * informed consent in adults * successful percutaneous coronary intervention (pci) \[no non-fatal myocardial infarction (mi)/stroke/repeat target revascularization/bleeding/acute kidney injury\]. * academic research consortium-high bleeding risk (arc-hbr) score ≥ 4. exclusion criteria: * chronic use of warfarin or direct oral anticoagulant (doac). * unsuccessful pci (see above). * lesions with angiographic thrombus. * prior pci within 6 months. * planned pci or surgical intervention to treat any cardiac or noncardiac condition within 6 months. * high risk lesion/stent characteristics (\> 50% unprotected left main disease, bifurcation disease requiring 2 stents technique, rotational atherectomy. * vein graft. * unprotected left main intervention or history of definite stent thrombosis. * women of child-bearing age unless negative pregnancy test is done. * life expectancy \< 1 year. * known drug/alcohol dependence. * assessment that the patient will not be compliant with the study protocol.

Keywords: antiplatelet medications blood thinners stent thrombosis percutaneous coronary intervention
fertility study of women with chronic inflammatory rheumatism

Conditions: Arthritis, Psoriatic; Arthritis, Rheumatoid; Ankylosing Spondylitis; Chronic Juvenile Arthritis

Summary: etiopathogenesis of chronic inflammatory rheumatisms (cir) includes genetic, autoimmune and environmental factors. their impact on the quality of life is important, leading to a sometimes severe disability. thus they are likely to affect female fertility through several mechanisms, including autoimmune since the association between immunity and fertility has already been demonstrated in other autoimmune diseases. this study wants to evaluate and compare the birth rate between cir and control group.

data collection will be carried out using a questionnaire submitted to women in charge of the rheumatology department of the university hospital of toulouse and having agreed to participate: * women with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or chronic juvenile arthritis for the chronic inflammatory rheumatism group * women with a mechanical rheumatic pathology for the control group the primary endpoint was birth rate after spontaneous or induced pregnancy in patients who attempted to procreate, in the cir group and in the control group.

Eligibility criteria:
inclusion criteria: * patient with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, chronic juvenile arthritis, chronic inflammatory rheumatism * patient diagnosed before the age of 40 * patient having given her no opposition to her participation in research * for the control group: patient not suffering from chronic inflammatory rheumatism, having consulted in rheumatology for a mechanical pathology exclusion criteria: * patient\> 40 years old at the time of diagnosis * patient with insufficient medical data (treatments)

Keywords: chronic inflammatory rheumatism fertility procreation
bloodstream infection due to multidrug-resistant organisms - multicenter study on determinants of clinical outcomes

Conditions: Bloodstream Infection; Septic Shock

Summary: continual surveillance of both community-acquired and nosocomial bloodstream infections for specific target organisms. analysis of comorbidities, complications, bacterial resistance patterns, bacterial genomics (e. g. via wgs and mlst typing) for the determinants of clinical outcomes. the clinical outcomes are investigated both in the short-term (up until discharge) and the long-term (six months after index blood culture by standardized questionnaire). a predictive point-of-care score is to be developed based on these data to define high-risk patient populations requiring more intensive diagnostic and/or treatment regimens.


Eligibility criteria:
inclusion criteria: * at least 18 years old * informed consent given either by patient or guardian * inpatient * at least one blood culture positive for one of the following bacteria: staphylococcus aureus, enterococcus spp., escherichia coli, enterobacter spp., klebsiella spp., acinetobacter baumannii, pseudomonas aeruginosa exclusion criteria: * less than 18 years old * not capable of giving informed consent nor informed consent given by guardian * outpatient * no blood cultures positive for any of the target organisms

Keywords: bsi sf-36 clinical outcome whole genome sequencing predictive score bloodstream infection septic shock multi-resistant bacteria
removal of protein bound uremic toxins by modified plasma separation and adsorption combined with hemodialysis

Conditions: Uremia

Summary: the aim of this study is to examine removal of protein bound uremic substances by mfpsa in chronic hemodialysis patients. mfpsa is an extracorporal blood purification system developed for detoxification in acute liver failure by removal of protein bound as well as water soluble substances.

measurements of uremic protein bound substances before and after mfpsa and a preceding routine hemodialysis session.

Eligibility criteria:
inclusion criteria: * over the age of 18 * anuria * chronic hemodialysis dependence exclusion criteria: * no present history of bleeding episodes * cardiac diseases

Keywords: mfpsa uremic toxins protein bound toxins uremia chronic hemodialysis
the value of hba in the evaluation of idiopathic infertility

Conditions: Infertility

Summary: we would like to determine if hba® testing of sperm in couples with presumed idiopathic infertility will reveal lower binding percentages than in couples with an identifiable cause of infertility either male factor or tubal factor

we would like to determine if hba® testing of sperm in couples with presumed idiopathic infertility will reveal lower binding percentages than in couples with an identifiable cause of infertility either male factor or tubal factor we would like to determine if patients with abnormal hba binding have decreased ivf outcome: decreases clinical pregnancy rate, implantation rate, and increased miscarriage rate

Eligibility criteria:
inclusion criteria: * . all groups will include females under 40 years of age undergoing 1st ivf cycle 3 groups 1. abnormal semen analysis (sperm count \<10 million/ml and /or rapid progressive motility \< 50 %, who morphology \<30%) normal hsg , normal ovarian reserve testing and ovulation testing 2. unexplained infertility- normal ovarian reserve testing and ovulation testing (fsh\ 1.0) normal ovulatory cycles, normal who semen analysis. normal tubes on hsg or laparoscopy 3. tubal infertility as assessed by hsg or laparoscopy exclusion criteria: * women over 40, prior failed ivf
comparison of intubation with direct laryngoscopy or videolaryngoscopy in an hemoptysis simulated situation on human cadaver embalmed with thiel's method

Conditions: Laryngoscope; Hemoptysis; Simulation; Cadaver; Intubation; Difficult or Failed

Summary: our study first aims to develope a realistic cadaver model of hemoptysis based on thiel's embalmed cadavers. secondly, participants will intubate the hemoptysis cadaver model with (a) the direct laryngoscopy with macintosh blade, (b) the videolaryngoscopy with mcgrath xblade and (c) the videolaryngoscopy with mcgrath xblade and a suction advance before the optic of the camera. we hypothesis that, in simulated hemoptysis on the thiel's embalmed cadaver, the rate of failed intubation at first try will be different depending on the laryngoscope used.

for the simulation of hemoptysis, we will need to use the thiel's embalmed cadaver, who's realism is established, create a synthetic form of blood resembling real blood by its viscosity and color for the simulation and elaborate the dynamic interface of the simulation of hemoptysis. the quantity and way of administration of the blood through the trachea will be tested to obtain a realistic hemoptysis as seen in supraglottic. for the simulation, we will compare the efficiency of intubation, judged by the failure rate of intubation on first try, for (a) the direct laryngoscopy with macintosh blade, (b) the videolaryngoscopy with mcgrath xblade and (c) the videolaryngoscopy with mcgrath xblade with the suction advanced before the camera. we will also measure the time to intubation, the failure rate of intubation, the suction use and the difficulty of intubation as reported by the participants.

Eligibility criteria:
inclusion criteria: * all wiling doctors and medical residents in the departments of anesthesiology, emergency medicine and intensive care * experience with the technique of intubation using videolaryngoscopy and direct laryngoscopy. exclusion criteria: * refusal to participate

Keywords: videolaryngoscopy thiel's embalmed cadaver